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Purpose/Objective: The use of diffusion MRI as a biomarker 
of response to therapy has been investigated in several 
preclinical and clinical studies. Recently the kurtosis model 
(see eq (1)) has been introduced to better characterize the 
DWI signal. The aim of this work is to measure the change of 
Diffusion (D) and Diffusional Kurtosis (k) in the healthy 
prostate tissue and in the tumour after radiation therapy. 
Materials and Methods: Ten patients with biopsy-proven 
prostate cancer, underwent diffusion weighted MRI (1.5 T) at 
b values (0, 500, 1000, 1500 s/mm2) before and after 
radiation therapy with curative intent (table1).  
A total of 31 lesions were identified at pre treatment MRI. 
Median time between end of therapy and MRI scan was 100 
days (max 221, min 77). 
Change in Diffusion and Diffusional Kurtosis (D, k) were 
estimated in the healthy prostate gland and in the cancer, 
through the relation (1): 
(1) ln[S(b)]=ln[S(0)]-bD+1/6D2b2k 




Results: Results are shown in fig1. The mean Diffusion value 
(1767 µ mm2/s) increases significantly (p<0.001) in tumour 
after therapy (pre treatment value 1295 µ mm2/s) and 
decreases in the healthy tissue (1838 µ mm2/s post 
treatment vs 2097 µ mm2/s pre treatment, p<0.05). 
Diffusional Kurtosis decreases significantly (p<0.01) in the 
tumour (1.3 vs 1.01) and shown not significant variation after 
therapy in the healthy prostate tissue (0.92 post-treatment vs 
0.86 pre-treatment). 
 
Conclusions: The measure of the diffusion properties of 
water in prostate carcinoma and in the healthy prostate 
tissue, before and after curative radiation therapy, is able to 
characterize the response to the irradiation. This study 
indicated that Diffusional Kurtosis is a promising biomarker 
for evaluation of tumour response to radiation therapy and 
can be used for follow-up.   
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Major progress in modern oncological treatment over the last 
decades has turned cancer increasingly into a more chronic 
and less life threatening disease and has led to an increasing 
number of cancer survivors. Therefore, in addition to 
classical clinical endpoints in cancer studies like survival, 
disease control rates and physician assessed morbidity, 
health-related quality of life and patient reported outcomes 
have considerably gained importance, as many patients have 
to face potential impairments for a long time.  
Furthermore, the increasing use of highly effective combined 
treatments raises concerns about the impact of morbidity on 
patients' quality of life. Health-related quality of life 
describes ‘the patient’s subjective perception of the impact 
of his disease and its treatment(s) on his/her daily life, 
physical, psychological and social functioning and well-
being’, according to the European Medicines Agency [EMA 
2005]. 
Traditional morbidity grading systems, especially the most 
frequently used Common Terminology Criteria of Adverse 
Events (CTCAE) of the US National Cancer Institute, involve 
an assessment by physicians with a comprehensive translation 
of patients’ narrative statements into medical terms and 
grades, with or without interpretation of their impact on 
activities of daily life, decisions about medical interventions, 
analytic (test) results and objective findings of examination 
[Trotti et al. 2007]. CTCAE morbidity endpoints offer 
therefore a wide range of clinical interpretation and have 
shown only a moderate inter-observer reliability [Atkinson et 
al. 2012].  
In comparison, patient reported outcomes represent a 
subjective evaluation in terms of quantifying frequency 
and/or intensity of symptoms and/or their impact on 
activities of daily life. They are assessed directly from the 
patient, mainly with questionnaires and without any clinical 
interpretation [Basch et al. 2012]. Therefore, they provide 
the most direct feedback reflecting the patients’ experience 
with disease and treatment and are increasingly recognized 
as reliable and valid endpoints in clinical studies. 
Several reports in literature indicate substantial variations 
between physician assessed morbidity and patient reported 
symptoms, mainly suggesting underreporting of milder to 
moderate symptoms in physician assessed morbidity [Fromme 
et al. 2004, Vistad et al. 2008, Davidson et al. 2007, Velikova 
et al. 2001, Kirchheiner et al. 2012]. 
From a methodological point of view, comparisons are 
restricted, as the physician assessed grading system and the 
answer categories of patient reported symptoms in a 
questionnaire do not follow a linear association. 
Nevertheless, it has been shown that discrepancies are 
frequently observed, if the patient reports substantial 
symptoms, which are not recognized by the physician in the 
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according morbidity scoring to any degree (Grade 0) 
[Kirchheiner et al. 2012]. 
Several explanations for discrepancies were hypothesized in 
literature, either related to patients or related to physicians. 
On the one hand, physicians may put more emphasis in 
clinical trials on identifying severe or life threatening 
morbidity. Furthermore, it may be questioned how general or 
specific physicians ask about symptoms in follow-up due to 
time restriction and how much information of the 
communication process is altered or lost [Atkinson et al, 
2012, Vistad et al. 2008, Davidson et al. 2007]. On the other 
hand, the patients’ narrative statements about symptoms 
strongly depend on individual factors, like psychological 
coping strategies, the patient– physician relationship, 
communication factors like interpersonal sympathy and trust, 
and the setting during medical encounter [Kirchheiner et al. 
2012]. 
In conclusion, patient reported outcomes are of high 
additional value and should be incorporated in clinical trials 
as a complementary assessment to physician assessed 
morbidity in order to give a more detailed and complete 
picture of the subjective symptom burden, especially in 
situations of low grade morbidity, which may be underrated 
by physicians.  
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Well informed patients and patient advocates have a key role 
to play in the implementation of patient-centred clinical 
research strategies and approval processes, access to 
treatments and treatment optimisation approaches. In an era 
of growing demand and emphasis on both quality and 
sustainability of healthcare, it is critical to involve patients in 
the R&D process more than just being participants in trials.  
New treatments are not  just about clinical efficacy: 
Different patients want different things, e.g. better survival 
vs. other patient-relevant endpoints, managing their own 
health vs. getting guidance and being taken care 
of, maximum disease control vs. focus on maintaining quality 
of life, outpatient treatment vs. hospital-based care, ability 
to work and have a social life, impact of family and family 
planning, and many more. The pack of patient priority might 
be a key reason that a majority of clinical trials are delayed 
due to a lack of willingness to participate, and subsequently 
lack of recruitment. 
Research design and conduct requires at a very early stage to 
better understand the patients' priorities and meeting unmet 
patient needs - which can only come true by involving 
patients and patient organisations as valuable partners and in 
delivering multidisciplinary care and information. 
In many disease areas, patients are already actively engaging 
in the many processes involved in the development of new 
treatments today: from contributing to protocol design, 
informed consent and ethical review - to the overall 
medicines development process, marketing authorization and 
healthcare policy. Involving patients can accelerate research 
and make it more effective.  
But in reality, are they involved enough on a broader, 
systematic level? Is all this a myth or reality? 
This presentation will look into e.g. what patients want to 
know about clinical trials, how to turn informed consent into 
an opportunity, how patient advocates are involved in clinical 
research design today, and how patient advocates are 
trained to be knowledgeable partners for researchers. 
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Purpose/Objective: Recent Monte Carlo (MC) studies have 
shown that plastic scintillation detectors, such as the Exradin 
W1 (SI), require negligible corrections to the dose 
measurements. However, the production of Cerenkov (CRV) 
light in the optical fiber may still perturb significantly the 
measurement. A method is required to decouple the CRV 
from the scintillation signal. The purpose of this work was to 
validate the accuracy of the W1 in the measurement of 
output factors (OF) and to explore possible limitations of the 
CRV calibration procedure in small fields. 
Materials and Methods: Reading ratio (RR) measurements 
with the W1 were performed for field sizes of 0.5 x 0.5, 1 x 1 
and 2 x 2 cm2 (depth = 5 cm). The W1 was positioned 
perpendicular to the CAX (perp) in solid water (res = 3 mm) 
and parallel (//) to the CAX in water (res = 1 mm). The 
measurements were repeated 4 times, each set acquired on a 
different week. The spectrum calibration method was 
performed in each set-up to account for the CRV signal. The 
W1 RRs were compared to the expected RRs calculated using 
MC simulations of an accurate accelerator model with the 
detector modeled in the dose calculation. The RRs (//) were 
also compared to the expected OFs in water derived using: i) 
MC simulations, ii) the W1 RR (perp) deconvolved for volume 
averaging, iii) the microLion (PTW) and D1V diode (SI) RRs 
with MC correction factors applied and iv) the RRs of an 'in-
house' developed scintillator (PSD) of similar design 
characteristics to the W1. In order to explore possible 
variations of the CRV correction in small fields, varying 
lengths of the W1 and PSD optical fiber were irradiated, 
while the scintillating volume was completely shielded by 
lead blocks. Under this set-up configuration, spectral analysis 
of the PSD was performed to evaluate potential spectral 
distribution changes that may alter the CRV correction.  
Results: For the W1 RRs (//) an over-response of the level of 
3.6% was observed for the 0.5 x 0.5 cm2 relative to the 
expected MC RRs. An over-response ranging from 3% - 4.5% 
was also observed relative to the expected OFs for the 0.5 x 
0.5 cm2 (fig. 1a) The W1 RRs (perp) agreed within 1% with the 
expected MC RRs. The fiber irradiations exhibited a 
dependency of the CRV correction to the W1 irradiated fiber 
length (fig. 1b). The PSD spectral analysis did not exhibit any 
